Insulin Dosing in Diabetic Patients With End Stage Renal Disease (ESRD) or Hemodialysis

Dosing Strategies in Diabetic Patients With End Stage Renal Disease (ESRD) or Hemodialysis (DOSE-HD Study)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02083133

Acronym

DOSE-HD

Enrollment

496

Registered

2014-03-11

Start date

2013-10-01

Completion date

2017-05-17

Last updated

2023-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Hypoglycemia, Insulin Dosing, Renal Dysfunction

Keywords

Diabetes, Renal Failure, Dialysis, End Stage Renal Disease, Hypoglycemia

Brief summary

The purpose of this study is to assess whether the current recommendation for a 50% dose reduction in insulin for diabetic patients with a creatinine clearance (CrCl) ≤15 mL/min or on hemodialysis results in an increased number of hypoglycemic episodes.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

* Inpatient men and women 18 years of age and older with a diagnosis of type 2 diabetes mellitus (T2DM) with CrCl ≥60, 16-59 or ≤15 milliliters/minute.

Exclusion criteria

* Patients less than 18 years of age, pregnant patients

Design outcomes

Primary

Measure	Time frame
Hypoglycemia	Last 5 years

Countries

United States

Outcome results